For most of his 18 years at Intel, Bryce Olson has been a self-described technical evangelist, promoting the company’s desktop and server platforms and its e-commerce and web-hosting services with corporate events and sales campaigns.

Then, in 2014, he found out that he had an aggressive prostate cancer. So he turned his marketing expertise at Intel toward more personally meaningful challenges. He also wanted to promote himself as a way for scientists to try out new cancer therapies targeting specific genes. And he wanted others to learn about and take advantage of these experimental but promising treatments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • it would be a great ideal, at we are helping pple with cancer as we partner with donors

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy